Stockreport

Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed [Yahoo! Finance]

Ionis Pharmaceuticals, Inc.  (IONS) 
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ionispharma.com
PDF – Phase 3 enrollment completed in CORE, CORE2 and ESSENCE evaluating olezarsen for the treatment of severe hypertriglyceridemia, with results expected in 2H 2025 – CA [Read more]